Ignite Creation Date:
2025-12-24 @ 4:52 PM
Ignite Modification Date:
2026-01-01 @ 11:47 PM
Study NCT ID:
NCT04250350
Status:
COMPLETED
Last Update Posted:
2023-02-24
First Post:
2020-01-30
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic Dermatitis
Sponsor:
Eli Lilly and Company
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-02-11
Start Date Type:
ACTUAL
Primary Completion Date:
2022-04-20
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-06-22
Completion Date Type:
ACTUAL
First Submit Date:
2020-01-30
First Submit QC Date:
None
Study First Post Date:
2020-01-31
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2022-12-15
Results First Submit QC Date:
None
Results First Post Date:
2023-02-24
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-01-30
Last Update Post Date:
2023-02-24
Last Update Post Date Type:
ACTUAL